Test Price
2,800 AED✅ Home Collection Available
DNAAF1 Gene Primary Ciliary Dyskinesia Type 13 – Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Complimentary telephonic post‑test result interpretation by DHA-licensed specialist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This DNAAF1 gene NGS test detects pathogenic variants causing Primary Ciliary Dyskinesia Type 13 (PCD13), enabling targeted diagnosis in patients with chronic respiratory infections, sinusitis, and situs inversus. It covers all coding exons and splice sites via high-throughput sequencing with >99% analytical accuracy.
Diagnostic Precision Compared
| Feature | Our DNAAF1 NGS Test | Standard Gene Panel (Limited) |
|---|---|---|
| Methodology | Full‑gene NGS + MLPA backup | Targeted genotyping only |
| Turnaround Time | 3‑4 Weeks | 6‑8 Weeks |
| Diagnostic Sensitivity | >99.9% | ~95% (misses novel variants) |
| Clinical Relevance | Confirms PCD13 subtype & guides specific management | May require reflex testing |
Physician Insight & Safety Protocols
“A positive DNAAF1 result confirms the genetic basis of primary ciliary dyskinesia type 13, but must be correlated with clinical history, nasal nitric oxide, and ciliary ultrastructure to personalise treatment. Negative results do not rule out other genetic causes, and genetic counselling is essential for family planning. This test empowers families with clarity, yet it complements—not replaces—your physician’s comprehensive evaluation.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory
Do not discontinue any prescribed medication without consulting your treating physician. Genetic results influence long‑term care but never replace acute medical management.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria:
- Active severe respiratory infection requiring hospitalisation
- Unwillingness to undergo pre‑test genetic counselling
Seek Immediate Medical Attention if:
- Sudden worsening difficulty breathing or cyanosis
- Signs of pneumothorax (sharp chest pain, shortness of breath)
- High fever unresponsive to antibiotics
Home collection is available only when the patient is clinically stable. In an emergency, call 998 or visit the nearest ER.
Patient FAQ & Clinical Guidance
1. What is the DNAAF1 gene test and how does it diagnose Primary Ciliary Dyskinesia Type 13?
The DNAAF1 gene test uses next-generation sequencing to identify pathogenic variants in the DNAAF1 gene, confirming a diagnosis of Primary Ciliary Dyskinesia Type 13 with >99.9% accuracy. It analyses all coding exons, enabling detection of even rare mutations responsible for ciliary dysfunction, chronic ear/sinus infections, and situs inversus.
2. Who should consider this DNAAF1 genetic test?
This test is recommended for children and adults with persistent respiratory infections and suspected ciliary dysfunction, especially when situs inversus is present. Ideal candidates include individuals with chronic otitis media, sinusitis, bronchiectasis, and unexplained infertility, or those with a family history of primary ciliary dyskinesia.
3. How is the test performed and what is the turnaround time?
Your DNA sample, collected via painless blood draw or buccal swab, undergoes comprehensive NGS analysis with results delivered in 3–4 weeks. The process requires only a small whole-blood sample; no fasting is needed, and genetic counselling is included before and after testing to ensure clear understanding of the outcomes.
UAE Regulatory & Data Privacy Adherence
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): Patient data is processed solely for diagnostic purposes and stored within UAE‑sovereign infrastructure; no cross‑border transfer without explicit consent.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: All electronic health data handling complies with this law.
- Federal Decree-Law No. 4 of 2016 on Medical Liability: Clinical testing safety and patient consent adhere to this law.
- ISO 9001:2015 Certified: Certificate INT/EGQ/2509DA/3139 – quality management across all laboratory and phlebotomy workflows.
- DHA Facility License Number: 1143
- Home Collection Licence: Mobile phlebotomy service holds an additional endorsement for domiciliary sampling.
Patient support: +971 54 548 8731 (WhatsApp/call). All reports are delivered securely through DHA‑approved digital channels.
Clinical & Logistical Metadata
| Test Name | DNAAF1 Gene Primary Ciliary Dyskinesia Type 13 – Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood or buccal swab |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | Q34.8 |
| LOINC Code | 51945-1 |
| DHA Facility License & Address | License No: 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians